Onco Actu du 7 octobre 2015

	3.1 Tabac
FDA launches national public education campaign to prevent and reduce tobacco use among multicultural youth [FDA] “Fresh Empire” empowers teens who identify with hip-hop community to live tobacco free.
	4.5 Dép., diag. & prono. - Colorectal
Exact Sciences Shares Plunge, Questions Arise for Insurers, Doctors [Xconomy] The task force said that computed tomography colonography and Cologuard might be useful in “select clinical circumstances.” “However, there is less mature evidence to support these methods, resulting in greater uncertainty about their net benefits and the most appropriate situations in which to use them,” the task force wrote.
Public Comment on Draft Recommendation Statement and Draft Evidence Review: Screening for Colorectal Cancer [US Preventive Services Task Force] To support its review of this topic, the Task Force also commissioned a decision modeling study that is posted with these materials.
Exact Sciences Tumbles on Colon Cancer Screening Snub [TheStreet] Exact Sciences CEO Kevin Conroy, speaking on a Tuesday morning conference call, said the decision by the U.S. Preventive Services Task Force to omit Cologuard from its draft list of recommended colon cancer screening tests was "different from what we and most people expected."
	4.8 Dép., diag. & prono. - Droit
Patient wins high court challenge against company's cancer gene patent [The Guardian] In an unanimous decision on Wednesday, the high court found that an isolated nucleic acid, coding for a BRCA1 protein, with specific variations from the norm that are indicative of susceptibility to breast cancer and ovarian cancer was not a “patentable invention”.
	5.12 Immunothérapies
The Landscape of Cancer: Immunotherapy Shining Through [The OBR Blog] Kantar Health’s newly developed CancerLandscape™ platform identified eight immunotherapy drugs in Phase 3 clinical trials in the U.S., with 13 in Phase 2 and 17 in Phase 1; 41 drugs that target PD-1 alone are in various stages of development, many in preclinical development that may never make it to clinical trials.
Investigating an Alternative Approach to Cancer Immunotherapy: Eliminating Immune System-suppressing Treg Cells [CANCER RESEARCH Catalyst] In the phase Ia clinical trial reported in Clinical Cancer Research, the researchers evaluated whether using a therapeutic antibody called KW-0761 (mogamulizumab), which targets the protein CCR4, would eliminate Tregs in the blood of patients with lung or esophageal cancer.
Transforming Cancer Treatment with Immunotherapy (TechVision) [ReportLinker] This research service brings out the emerging trends cancer immunotherapy on a global scale, through a detailed strategic assessment of the industry environment.
	5.2 Pharma
Advaxis offers a tardy defense after FDA puts cancer vaccine on hold [FierceBiotech] That didn't sit well with investors, who immediately triggered a 36% drop in share price after the stock began trading again.
Advaxis Reports Clinical Hold of Investigational Agent Axalimogene Filolisbac [Advaxis] Advaxis Expects That This Clinical Hold Will Be Resolved Expeditiously and Without Significant Interruption to the HPV Clinical Development Program.
FDA puts clinical hold on Advaxis cancer drug [Reuters] Advaxis said the FDA has asked for additional information to prove that the drug did not contribute to the patient’s death. Axalimogene filolisbac is being tested in patients with Human Papilloma Virus-associated cancers.
	5.2.1 Pharma - Partenariats
MD Anderson, Theraclone Sciences form OncoResponse [MD Anderson Cancer Center] OncoResponse will use Theraclone’s I-STAR™ immune repertoire screening technology to identify therapeutic antibodies against novel targets from immuno-oncology treated patients.
	5.3 Traitements - FDA, EMA,...
Why the FDA should take more chances on riskier drugs [Pharmalot] Right now, the Food and Drug Administration will not approve a drug if there is more than a 2.5 percent chance that it doesn’t work — no matter which disease or how poor the prognosis. There is a cold logic to this approach. And in a recently published paper, Massachusetts Institute of Technology finance professor Andrew Lo took the FDA to task for not being more flexible.
	5.4 Traitements - Economie
Fast-tracked skin cancer drug pembrolizumab gets approval [BBC News] The National Institute for Health and Care Excellence says pembrolizumab is cost-effective to use in patients who have already tried and not benefited from another drug called ipilimumab.
	6. Lutte contre les cancers
Freezing Ovaries Before Cancer Treatment May Preserve Fertility [NPR] Danish researchers looked at 41 women who underwent the procedure between 2003 and 2014. They found that about one-third who tried to have a baby actually succeeded.
	6.1 Observation
First HIV, then cancer [Hutch News] As people with HIV live longer, they are developing cancers at higher rates than the general population.
	6.11 Patients
Henning Mankell: ‘Eventually the day comes when we all have to go’ [The Guardian] The late Wallander author, who died this week, was writing in the Guardian about life with cancer. In his final entry, he reflects on fearful nights lying awake as the ‘cold winds sweep in’.
	6.6 Publications
There’s “no evidence” research was conducted at all in retracted cancer paper [Retraction Watch] The Editors of Cancer Epidemiology received a communication from the Chief of the Department of Hand Surgery at Wuhan Union Hospital, the institution where the authors stated that the research took place, who confirmed that the hospital had not treated the number of patients reported in the paper and that there was no evidence that the research on MPNST was conducted at all.
	6.7 DMP, Big Data & applis
Roche CEO: Big Data needs Big Pharma, and vice versa [FiercePharma] Given that healthcare's future will depend on digital, is Google a competitor--or a potential partner? "I don't know yet," Schwan said. "We will see how things go."